We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+15.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.45B
AUM Growth
+$7.66M
Cap. Flow
-$5.91M
Cap. Flow %
-0.41%
Top 10 Hldgs %
77.82%
Holding
53
New
5
Increased
6
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$13.6M
2
VSTM icon
Verastem
VSTM
+$10.7M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$8.25M
4
DCTH icon
Delcath Systems
DCTH
+$7.39M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$7.02M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$21.7M
2
LEGN icon
Legend Biotech
LEGN
+$11.8M
3
GERN icon
Geron
GERN
+$7.85M
4
BLU
BELLUS Health Inc.
BLU
+$7.32M
5
MRUS
Merus
MRUS
+$6.51M

Sector Composition

Rank Sector Weight
1 Healthcare 99.19%
2 Materials 0.55%
3 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRS
26
DELISTED
Amyris Inc.
AMRS
$7.98M 0.55%
7,750,828
– –
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$7.7M 0.53%
856,008
– –
GTH
28
DELISTED
Genetron Holdings Limited ADS
GTH
$7.56M 0.52%
2,708,058
– –
TIL icon
29
Instil Bio
TIL
$48.3M
$6.88M 0.47%
624,339
– –
DCTH icon
30
Delcath Systems
DCTH
$422M
$6.87M 0.47%
+1,178,787
New +$7.39M
DYN icon
31
Dyne Therapeutics
DYN
$4.7B
$6.5M 0.45%
577,642
– –
WHWK
32
Whitehawk Therapeutics
WHWK
$190M
$6.46M 0.45%
509,572
– –
SERA icon
33
Sera Prognostics
SERA
$79.9M
$6.12M 0.42%
1,856,011
– –
IOBT
34
DELISTED
IO Biotech
IOBT
$5.9M 0.41%
3,015,545
– –
DBVT
35
DBV Technologies
DBVT
$799M
$5.15M 0.36%
270,888
– –
BOLT icon
36
Bolt Biotherapeutics
BOLT
$7.67M
$4.96M 0.34%
193,565
– –
ARWR icon
37
Arrowhead Research
ARWR
$11.9B
$4.9M 0.34%
137,411
– –
IOVA icon
38
Iovance Biotherapeutics
IOVA
$1.82B
$4.61M 0.32%
655,057
– –
CLNN icon
39
Clene
CLNN
$64M
$3.71M 0.26%
+226,031
New +$4.41M
IMPL
40
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$3.66M 0.25%
2,884,789
– –
ALGS icon
41
Aligos Therapeutics
ALGS
$26.2M
$3.44M 0.24%
141,881
– –
BCAB icon
42
BioAtla
BCAB
$5.46M
$1.91M 0.13%
12,744
– –
FULC icon
43
Fulcrum Therapeutics
FULC
$273M
$1.81M 0.13%
550,000
– –
IMUX icon
44
Immunic
IMUX
$190M
$1.59M 0.11%
63,218
– –
CDXS icon
45
Codexis
CDXS
$151M
$1.09M 0.08%
388,144
– –
RZLT icon
46
Rezolute
RZLT
$454M
$969K 0.07%
489,473
– –
QTTB icon
47
Q32 Bio
QTTB
$466M
$328K 0.02%
20,559
– –
DTIL icon
48
Precision BioSciences
DTIL
$180M
$73.8K 0.01%
4,675
– –
LEGN icon
49
Legend Biotech
LEGN
$3.59B
– –
-244,375
Closed -$11.8M
MRUS
50
DELISTED
Merus
MRUS
– –
-353,600
Closed -$6.51M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Vivo Capital held 53 positions worth $1.45B, up 0.53% from $1.44B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Vivo Capital's Q2 2023 filing shows 5 new, 6 increased, 4 reduced and 5 closed positions. Its largest new stake was Icosavax, Inc. Common Stock: 1,704,568 shares worth $16.9M. The largest sale was Vaxcyte, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Materials and Consumer Staples.

  • Vivo Capital's largest Q2 2023 buy was Icosavax, Inc. Common Stock: 1,704,568 shares worth $16.9M.
  • Vivo Capital added most to Gracell Biotechnologies Inc. American Depositary Shares in Q2 2023, an estimated $7.02M increase.
  • Vivo Capital's biggest Q2 2023 reduction was Geron, cutting an estimated $7.85M.
  • Vivo Capital fully exited Vaxcyte in Q2 2023, selling an estimated $21.7M.
  • Vivo Capital's ten largest holdings make up 78% of its $1.45B portfolio in Q2 2023.
  • Vivo Capital opened 5 new positions and closed 5 in Q2 2023.
  • Vivo Capital's portfolio value rose 0.53% quarter-over-quarter to $1.45B.

Based on Vivo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.